Sickle cell anemia
Methodology & AI Transparency ⓘ
Sickle cell anemia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Sickle cell anemia is an ICD-10-CM indexed diagnosis (D57.1) within Anemia, Clotting & Blood Disorders.
- 2 Real-world patient consensus: Federal ICD-10-CM code D57.1 categorizes Sickle cell anemia under Anemia, Clotting & Blood Disorders.
- 3 Typical cash cost range: Primary evaluation for Sickle cell anemia incorporates complete blood count in Sickle cell anemia (D57.1: with peripheral smear) and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Sickle cell anemia monitoring tracks Hemoglobin, Hematocrit & in Sickle cell anemia (D57.1: MCV) toward Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D57.1).
Ask our AI Specialists anything about Sickle cell anemia
What Is Sickle cell anemia?
Sickle cell anemia is an ICD-10-CM indexed diagnosis (D57.1) within Anemia, Clotting & Blood Disorders. Clinical evaluation centers on complete blood count in Sickle cell anemia (D57.1: with peripheral smear) alongside serial Hemoglobin, Hematocrit & in Sickle cell anemia (D57.1: MCV) tracking (Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D57.1)) to guide individualized care.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Sickle cell anemia (D57.1) center on chronic inflammatory hepcidin in Sickle cell anemia (D57.1: iron sequestration). targeted blood & anemia interventions aim to normalize Hemoglobin, Hematocrit & in Sickle cell anemia (D57.1: MCV).
Common Symptoms & Clinical Signs
- • Presentation of Sickle cell anemia (D57.1): exertional fatigue, reduced in Sickle cell anemia (D57.1: stamina, pale conjunctiva,)
- • Secondary Sickle cell anemia clinical sign: restless legs, ice in Sickle cell anemia (D57.1: craving)
- • Symptom flares in Sickle cell anemia correlating with Hemoglobin, Hematocrit & in Sickle cell anemia (D57.1: MCV) deviation outside Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D57.1)
- • Functional blood & anemia impact requiring complete blood count in Sickle cell anemia (D57.1: with peripheral smear) evaluation (D57.1)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Sickle cell anemia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D57.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Anemia, Clotting & Blood Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Hemoglobin, Hematocrit & in Sickle cell anemia (D57.1: MCV) | Hgb 13.5–17.0 (M) / 12.0–15.5 (F) g/dL (D57.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin & in Sickle cell anemia (D57.1: Transferrin Saturation) | Ferritin 50–150 ng/mL; TSAT 20%–45% (D57.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Vitamin B12, Folate in Sickle cell anemia (D57.1: & Reticulocyte Count) | B12 > 500 pg/mL; appropriate marrow response (D57.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Sickle cell anemia
Treatment selection for Sickle cell anemia depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sickle cell anemia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Hydroxyurea for secondary stroke prevention in children with sickle cell anemia No participant had hydroxyurea therapy stopped for myelosuppression. Blood • 2023-02-23 • Phase III Randomized Trial | N = 101 | 88/100 | PMID 36322937 ↗ |
| Can This Approach Help? Inside the Latest Research on Evidence of Crizanlizumab Showing Reductions in Vaso-Occlusive Crises and Opioid Crizanlizumab demonstrated potential benefits in attenuating VOC episodes, irrespective of SCD genotype and prior hydroxyurea use, and in lowering opioid usage. European journal of haematology • 2025-02-15 • Phase III Randomized Trial | N = 112 | 82/100 | PMID 39473076 ↗ |
| Can This Approach Help? Inside the Latest Research on Impaired pubertal development and testicular hormone function in males with The hormonal level assessment of testosterone at baseline and at 24, 48 and 72 h after hCG stimulation showed no significant differences between the groups studied. Blood cells, molecules & diseases • 2015-01-15 • Randomized Controlled Trial | N = 15 | 82/100 | PMID 25190051 ↗ |
Sickle cell anemia Patient Community & “People Like Me” Threads
Filter Sickle cell anemia community threads and patient logs by age, biological sex, dosage, and treatment duration.